Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 5 | - | +5,89 % | ||
| AMGEN | 4 | 27 | +0,02 % | ||
| BIOMARIN PHARMACEUTICAL | 4 | 12 | -1,57 % | ||
| CYTOKINETICS | 4 | 1 | 0,00 % | ||
| TWIST BIOSCIENCE | 3 | - | -3,17 % | ||
| BIONTECH | 2 | 13 | -0,27 % | ||
| CASTLE BIOSCIENCES | 2 | 2 | +0,10 % | ||
| SYNDAX PHARMACEUTICALS | 2 | 1 | -1,64 % | ||
| AMNEAL PHARMACEUTICALS | 2 | - | -0,71 % | ||
| ADAPTIVE BIOTECHNOLOGIES | 2 | - | +0,18 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:26 | Why Cytokinetics, Inc. (CYTK) Went Down On Friday | 1 | Insider Monkey | ||
| 11:50 | Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr | 5 | capitalmarket.com | ||
| 10:13 | Unglaubliche Prognose für Montag setzt CureVac Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | Felix Haupt | |||
| 01:31 | Why Edgewise Therapeutics Stock Popped This Week | 4 | The Motley Fool | ||
| Fr | Syndax Pharmaceuticals Q1 2025 Earnings Preview | 1 | Seeking Alpha | ||
| Fr | Liquidia Corporation: District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia | 48 | GlobeNewswire (Europe) | Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires... ► Artikel lesen | |
| Fr | Castle Biosciences Q1 2025 Earnings Preview | 1 | Seeking Alpha | ||
| Fr | What to Expect from Neurocrine Biosciences' Earnings | 9 | Benzinga.com | ||
| Fr | Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk | 2 | Benzinga.com | ||
| Fr | What's Next: Twist Bioscience's Earnings Preview | 1 | Benzinga.com | ||
| Fr | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 22 | GlobeNewswire (Europe) | BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| Fr | Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 40 | GlobeNewswire (Europe) | VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing... ► Artikel lesen | |
| Fr | Castle Biosciences, Inc.: New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer | 2 | GlobeNewswire (USA) | ||
| Fr | ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 21 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address... ► Artikel lesen | |
| Fr | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 21 | GlobeNewswire (Europe) | SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| Fr | 89bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Fr | Twist Bioscience Q2 2025 Earnings Preview | 2 | Seeking Alpha | ||
| Fr | BioNTech Q1 2025 Earnings Preview | 65 | Seeking Alpha | ||
| Fr | HALOZYME THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| Fr | A Look Into Biomarin Pharmaceutical Inc's Price Over Earnings | 1 | Benzinga.com |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .